Overall survival by race and ethnicity among men with metastatic castration-resistant prostate cancer (mCRPC) in the U.S. Medicare population.

Authors

Stephen J. Freedland

Division of Urology, Department of Surgery, Cedars-Sinai Medical Center and Department of Surgery, Durham Veterans Affairs Health Care System, Durham, NC

Stephen J. Freedland, Matthew Davis, Andrew J. Epstein, Bhakti Arondekar, Jasmina I. Ivanova

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

Poster Details

Meeting

2022 ASCO Quality Care Symposium

Session Type

Poster Session

Session Title

Poster Session A

Track

Cost, Value, and Policy,Health Care Access, Equity, and Disparities,Patient Experience

Sub Track

Cancer Outcome Disparities

Citation

J Clin Oncol 40, 2022 (suppl 28; abstr 144)

DOI

10.1200/JCO.2022.40.28_suppl.144

Abstract #

144

Poster Bd #

E13

Abstract Disclosures

FEATURED

Overall survival by race and ethnicity among men with metastatic castration-resistant prostate cancer (mCRPC) in the U.S. Medicare population.

Authors

Stephen J. Freedland

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Poster Details

Meeting

Session Type

Session Title

Track

Sub Track

Citation

DOI

Abstract #

Poster Bd #

Similar Posters

Poster

Racial and ethnic differences in presentation and clinical outcomes for pediatric rhabdomyosarcoma (RMS).

Poster

Poster

Analysis of patients with metastatic castration-resistant prostate cancer (mCRPC) treated with carboplatin-paclitaxel after multiple lines of treatment.

Poster

Clinical outcomes with systemic therapy given after progression on prostate specific membrane antigen radioligand therapy (PSMA-RLT) in patients with metastatic castration-resistant prostate cancer (mCRPC).